Multivesicular liposomes for oral delivery of recombinant human epidermal growth factor
- 170 Downloads
The purpose of the present study was to prepare multivesicular liposomes with a high drug loading capacity and to investigate its potential applicability in the oral delivery of a peptide, human epidermal growth factor (rhEGF). The multivesicular liposomes containing rhEGF was prepared by a two-step water-in-oil-in-water double emulsification process. The loading efficiency was increased as rhEGF concentration increased from 1 to 5 mg/mL, reaching approximately 60% at 5 mg/mL. Approximately 47% and 35% of rhEGF was released from the multivesicular liposomes within 6 h in simulated intra-gastric fluid (pH 1.2) and intra-intestinal fluid (pH 7.4), respectively. rhEGF-loaded multivesicular liposomes markedly suppressed the enzymatic degradation of the peptide in an incubation with the Caco-2 cell homogenate. However, the transport of rhEGF from the multivesicular liposomes to the basolateral side of Caco-2 cells was two times lower than that of the rhEGF in aqueous solution. The gastric ulcer healing effect of rhEGF-loaded multivesicular liposomes was significantly enhanced compared with that of rhEGF in aqueous solution; the healing effect of the liposomes was comparable to that of the cimetidine in rats. Collectively, these results indicate that rhEGF-loaded multivesicular liposomes may be used as a new strategy for the development of an oral delivery system in the treatment of peptic ulcer diseases.
Key wordsrhEGF Multivesicular liposomes Loading efficiency Oral delivery Peptide
Unable to display preview. Download preview PDF.
- Annaert, P., Kinget, R., Naesens, L., Clercq, E. D., and Augustijins, P., Transport, uptake and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonyl-methoxyethyl) adenine in anin vitro cell culture system of the intestinal mucosa (Caco-2).Pharm. Res., 14, 492–496 (1997).PubMedCrossRefGoogle Scholar
- Han, K., Lee, S. J., Kim, J. W., and Chung, Y. B., Oral bioadhesive gels of rhEGF for the healing of gastric ulcers.J. Kor. Pharm. Sci., 28, 99–107 (1998).Google Scholar
- Kirkegaard, P., Olsen, P. S., Poulsen, S. S., and Nexo, E. Epidermal growth factor inhibits cysteamine-induced duodenal ulcer.Gestroenterology, 85, 1277–1283 (1983).Google Scholar
- Konturek, S. J., Radecki, T., and Brzozowski, T., Gastric cytoprotection by epidermal growth factor.Gestroenterology, 81, 438–443 (1981).Google Scholar
- Li, H., Chung, S. J., Kim, D. C., Kim, H. S., Lee, J. W., and Shim, C. K., The transport of a reversible proton pump antabonist, 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across Caco-2 cell monolayers.Drug Metab. Dispos., 29, 54–59 (2001).PubMedGoogle Scholar